Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Blood|September 20, 2007
A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion techniqueStephan Mielke, Raquel Nunes, Katayoun Rezvani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 23, 2018
Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical VariablesScott R Solomon, Michael T Aubrey, Xu Zhang, et al.
Cancers|March 13, 2024
CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 TrialScott R Solomon, Bayard L Powell, Jamie Koprivnikar, et al.
Blood|May 5, 2007
Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host diseaseStephan Mielke, Katayoun Rezvani, Bipin N Savani, et al.
Blood|November 1, 2008
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantationAsad Bashey, Bridget Medina, Sue Corringham, et al.
The Lancet. Haematology|July 3, 2025
Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 studyPaolo Strati, Januario Castro, Aaron Goodman, et al.
Blood|April 2, 2014
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLJeffrey E Lancet, Jorge E Cortes, Donna E Hogge, et al.
Blood Advances|March 16, 2021
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analysesTara L Lin, David A Rizzieri, Daniel H Ryan, et al.
Blood Advances|September 23, 2022
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCLJeremy S Abramson, Patrick B Johnston, Manali Kamdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemiaGail J Roboz, Todd Rosenblat, Martha Arellano, et al.
Pageof 8